Daily non-political popular news in brief.
Penn's Abramson Cancer Center part of major phase III study for myeloma
11-21-2007 · EurekAlert!Researchers from the UPenn's Abramson Cancer Center announced today that findings from two international clinical trials show unprecedented survival for patients with myeloma, a cancer the blood-making cells of bone marrow. Findings show that with the oral drug lenalidomide, in combination with dexamethasone, patients significantly improved by all measures where previous treatments had failed -- including a median survival of nearly three years -- the longest median survival known for this difficult to treat patient group.
Read more »
Keywords: penn, abramson, cancer, center, part, major, phase, iii, study, myeloma
« Previous | Next »
Similar news on "Penn's Abramson Cancer Center part of major phase III study for myeloma":
- Participation in organized high school activities lowers risk of smoking 3 years after graduation
12-06-2007 · EurekAlert!
Researchers from the Abramson Cancer Center of the University of Pennsylvania reported today that students who participate in high school sports or individual physical activity are less likely to smoke than their classmates. The new study indicates that the protective effect of participation extends at least three years beyond graduation. The Penn team discovered, however, that girls do not derive the same level of protection from school sports as do boys.
Similar news · Read more »
- New neuroimaging study identifies 'brain signature' for cigarette cravings
12-18-2007 · EurekAlert!
A new brain imaging study by researchers in the Abramson Cancer Center of the University of Pennsylvania shows that cigarette cravings in smokers who are deprived of nicotine are linked with increased activation in specific regions of the brain. Using a novel method of measuring brain blood flow developed at Penn, this study is the first to show how abstinence from nicotine produces brain activation patterns that relate to urges to smoke.
Similar news · Read more »
- Study produces conflicting findings on the use of anti-anemia drug in cancer patients
04-16-2007 · EurekAlert!
Results from a phase III drug trial indicate that an anti-anemia drug did not significantly decrease the need for blood transfusions in patients not on chemotherapy, and decreased overall patient survival when compared to placebo, according to researchers from the UCLA Medical Center at the 2007 Annual Meeting of the American Association for Cancer Research.
Similar news · Read more »
- New hope for patients with chronic lymphocytic leukemia
12-04-2006 · EurekAlert!
Patients treated with lenalidomide for relapsed chronic lymphocytic leukemia (CLL) or disease that no longer responds to chemotherapy have experienced a major response to therapy, according to a phase II study conducted by Asher Chanan-Khan, MD, Department of Medicine, Roswell Park Cancer Institute (RPCI). The results are published in the December 1 issue of the Journal of Clinical Oncology.
Similar news · Read more »
- Clinical data suggest potential versatility of ALIMTA-based regimens in lung cancer
06-02-2007 · EurekAlert!
ALIMTA (pemetrexed for injection) showed additional utility in the treatment of the most diagnosed type of cancer, according to data presented today at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO). Results from a Phase III study suggest that a first-line ALIMTA-based regimen may deliver less toxicity than a commonly used therapy in advanced non-small cell lung cancer (NSCLC). ALIMTA is manufactured and marketed by Eli Lilly and Company.
Similar news · Read more »
- CTRC enrolls first patients in Novel Phase II study for sarcoma -- Living virus destroys cancer cell
07-24-2007 · EurekAlert!
The Cancer Therapy & Research Center Institute for Drug Development, in collaboration with Oncolytics Biotech Inc., a biotechnology company, has enrolled the first two patients in a new Phase II clinical study for patients with various types of sarcomas that have metastasized to the lung. The novel anti-cancer therapy, REOLYSIN, is a living virus, not a chemotherapy drug, that is toxic to cancer cells but not harmful to normal cells.
Similar news · Read more »
- Investigating the measles virus as a tool to kill multiple myeloma
03-05-2007 · EurekAlert!
Mayo Clinic Cancer Center has opened a new Phase I clinical trial testing an engineered measles virus against multiple myeloma, a cancer of the bone marrow that currently has no cure.
Similar news · Read more »
- Mayo Clinic Cancer Center researcher finds mold by-product kills multiple myeloma
04-15-2007 · EurekAlert!
Mayo Clinic Cancer Center researchers have found that chaetocin, a by-product of a common wood mold, has promise as a new anti-myeloma agent. Results of their study, being presented today at the American Association for Cancer Research annual meeting, show the by-product to be more effective than currently used therapies at killing multiple myeloma cells.
Similar news · Read more »
- Bayer and Onyx announce pivotal Nexavar kidney cancer study published in NEJM
01-10-2007 · EurekAlert!
Bayer Pharmaceuticals Corporation (NYSE: BAY) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that the New England Journal of Medicine has published their pivotal Phase III trial demonstrating that Nexavar (sorafenib) tablets doubled median progression-free survival (PFS) in patients with advanced renal cell carcinoma (RCC), or kidney cancer.
Similar news · Read more »
- Revlimid data presented at ASCO stands to change the way physicians treat multiple myeloma
06-04-2007 · EurekAlert!
Findings from a Phase III study by the Eastern Cooperative Oncology Group (ECOG) were presented yesterday at the American Society of Clinical Oncology (ASCO) meeting in Chicago and demonstrate the impressive survival benefits of using Revlimid (lenalidomide) with reduced doses of the steroid dexamethasone.
Similar news · Read more »
